The accelerated cash burn in Q3 (from $876M to $694M) vs Q1's $128M net loss signals higher spending on casdatifan clinical trials and inflammation pipeline. Monitor the full Q3 10-Q for detailed P&L and updated cash runway guidance; the company's prior expectation of ~$600M year-end cash implies further burn of ~$94M in Q4, which would be a deceleration from Q3's pace.
Price Chart
Executive Summary
Arcus Biosciences disclosed a preliminary Q3 2026 cash balance of ~$694M, down from $876M at Q2 end and $1.01B at year-end 2025, reflecting continued R&D spend on casdatifan and pipeline programs. The filing is a routine preliminary cash update without full financial results, but the burn rate implies ~$182M spent in Q3 alone, accelerating from ~$134M in Q1 2026. No earnings or revenue figures were provided, and the company expects to end 2026 with ~$600M in cash per the prior quarter's guidance.
Key Facts
- Preliminary cash, cash equivalents and marketable securities of ~$694.0M as of September 30, 2026, down from $876M at March 31, 2026 and $1.01B at December 31, 2025.
- The estimate is preliminary and subject to completion of financial closing procedures; Ernst & Young has not audited or reviewed the figure.
- No revenue, EPS, or full financial results were disclosed in this filing.
- Cash runway was previously guided to last until at least the second half of 2028, with an expected year-end 2026 cash balance of ~$600M (from the Q1 2026 earnings release).
- The Q3 cash burn of ~$182M (from $876M to $694M) is higher than the Q1 2026 net loss of $128M, suggesting continued heavy investment in casdatifan and inflammation programs.
Financial Impact
Preliminary cash balance of $694M, down ~21% from $876M at Q1 end; quarterly cash burn of ~$182M.
Risk Factors
- Cash burn rate may exceed prior guidance if casdatifan trial enrollment or manufacturing costs accelerate further.
- No revenue or EPS data provided; the preliminary cash update alone does not confirm operational progress or pipeline milestones.
- The company is pre-revenue (clinical-stage biotech) with no approved products; reliance on partnership revenue (Gilead) and capital markets for funding.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-427829 |
| Document: 0001193125-26-427829-index-headers.html | 0001193125-26-427829 |
| Document: 0001193125-26-427829-index.html | 0001193125-26-427829 |
| Document: 0001193125-26-427829.txt | 0001193125-26-427829 |
| 8-K Data (Synthetic) | 0001193125-26-427829 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $18.47 | awaiting T+1 | — | $18.54 (−0.38%) |
Oct 22, 2026 3d ago | 424B5 | $19.36 | awaiting T+1 | — | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 424B5 | $19.36 $18.54 | ▲ +4.24% | ▲ +3.71% | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 8-K | $19.36 $18.54 | ▼ −4.24% | ▼ −3.71% | $18.54 (−4.24%) |
Oct 20, 2026 5d ago | 8-K | $23.75 $19.10 | ▼ −19.58% | ▼ −20.10% | $18.54 (−21.94%) |
Jul 9, 2026 15w ago | 144 | $28.92 $28.07 | ▼ −2.94% | ▼ −2.17% | $18.54 (−35.89%) |
Apr 21, 2026 26w ago | DEFA14A | $26.62 $25.13 | ▼ −5.60% | ▼ −5.20% | $18.54 (−30.35%) |
Apr 20, 2026 27w ago | 8-K | $22.74 $24.52 | ▼ −7.83% | ▼ −8.48% | $18.54 (+18.47%) |
Apr 8, 2026 28w ago | 144 | $23.28 $22.34 | ▼ −4.04% | ▼ −3.98% | $18.54 (−20.36%) |
Feb 25, 2026 34w ago | 8-K | $19.54 $20.37 | ▲ +4.25% | ▲ +4.73% | $18.54 (−5.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers